Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock
July 31, 2023 16:29 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new...
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis
July 25, 2023 07:00 ET
|
Tarsus Pharmaceuticals, Inc
XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the...
Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis
June 12, 2023 08:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus to Present at the Jefferies Global Healthcare Conference
June 05, 2023 08:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements
May 09, 2023 16:05 ET
|
Tarsus Pharmaceuticals, Inc
Continuing to build market awareness through disease education and deploying commercial leadership in anticipation of TP-03 August 25, 2023 PDUFA Presented health economics data suggesting a...
Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers
May 08, 2023 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Demodex blepharitis is a highly prevalent, yet often undiagnosed eyelid disease that impacts approximately 25 million eye care patients in the U.S. IRVINE, Calif., May 08, 2023 (GLOBE NEWSWIRE) --...
Tarsus to Participate at the Bank of America 2023 Healthcare Conference
May 03, 2023 16:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer
April 24, 2023 08:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements
March 13, 2023 16:05 ET
|
Tarsus Pharmaceuticals, Inc
Engaging with more than two-thirds of key optometrists and/or ophthalmologists, and top payers on Demodex blepharitis in anticipation of TP-03 August 25, 2023 PDUFA Completed enrollment of Ersa, a...
Tarsus to Present at Upcoming Investor Conferences
March 02, 2023 16:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...